OROPALLO CASE SERIES
The study showed how PuraPly® AM reduced wound size in chronic wounds that failed ~2 years of prior therapies.1
Prospective case series to assess the ability of PuraPly AM to manage bioburden, support granulation tissue formation, and support wound closure over 12 weeks in chronic, nonhealing wounds.
- A single-center, prospective case series (NCT03070925)
- Wounds were cleaned and prepared with sharp or mechanical debridement at initial visit
- PuraPly AM was applied at week 0 and then every 1-3 weeks thereafter
- At each visit, wounds were assessed for signs of infection, wound area and depth, and achievement of closure
- A total of 41 wounds were included in the ITT analysis
- Wound types included were pressure ulcers (18), surgical wounds (9), VLUs (5), DFUs (4), and other (5)
- Median baseline wound area was 7.2 cm2 and mean depth was 0.58 mm
- Mean wound duration was 103.1 weeks
- 73.2% (30/41) demonstrated an overall reduction in wound area over 12 weeks
- 36.6% (15/41) achieved complete wound closure with a mean time to closure of 6.7 weeks
- Increased granulation tissue was observed with healing of wounds
- Mean decrease in wound size of 7.5 cm2
SEE THE EFFECT PURAPLY AM HAS IN SUPPORTING HEALING OF REFRACTORY WOUNDS
See the effectiveness of PuraPly AM in patients with refractory wounds of various etiologies, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM can help your practice.
Please refer to the PuraPly AM Instructions for Use for complete prescribing information.
- Oropallo AR. Plast Reconstr Surg Glob Open. 2019;7:e2047.